Search clinical trials for: Factor Xa inhibitors

Total 87527 results

Population Health Research Institute
Bristol-Myers Squibb; Pfizer; Canadian Institutes of Health Research (CIHR); Me...

Completed

Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA)

Stroke | Atrial Fibrillation

United States, Spain, Canada, Belgium, United Kingdom, Denmark, Germany, Switzerland, Netherlands, Hungary, Norway, Czechia, Italy
Indiana University

Completed

RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding ((RAMBLE))

Venous Thromboembolism | Menstruation

United States
Bayer
Janssen Research & Development, LLC

Completed

Study Aims to Collect Information in Routine Clinical Practice in Italy About the Number of Patients Suffering From Irregularly Heart Beats Which Are Not Caused by a Heart Valve Problem (Non-valvular Atrial Fibrillation, NVAF) Who Stopped or Changed Rivaroxaban Treatment (RITMUS-AF)

Non-valvular Atrial Fibrillation

Italy
Bayer

Completed

Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort (OSCAR-US)

Treatment of Venous Thromboembolism in Cancer Patients | Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients

United States
Bayer
Janssen Research & Development, LLC

Completed

Study of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban (EMIR)

Atrial Fibrillation

Spain
Bayer
Janssen Scientific Affairs, LLC

Completed

Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France (BROTHER)

Atrial Fibrillation

France
Bayer
Janssen Research & Development, LLC

Completed

A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer (COSIMO)

Venous Thrombosis and Pulmonary Embolism

Italy, Germany, United Kingdom, France, Belgium, Canada, Netherlands, Spain, Denmark, Australia
Bayer
Janssen Research & Development, LLC

Completed

Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban) (FARAONIC)

Heart Failure

Spain
GWT-TUD GmbH

Completed

Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Subclinical Inflammation and High Cardiovascular Risk (MicroVasc-DIVA)

Type 2 Diabetic Patients

Germany
Bayer
Janssen, LP

Completed

Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem) (REATTAIN)

Atrial Fibrillation

Sweden
Bayer

Completed

A Study to Collect Data on the Treatment Pattern of Xarelto + Acetylsalicylic Acid in the Routine Clinical Practice in Patients Who Are Suffering From a Condition That Narrows the Blood Vessels Supplying the Heart and / or a Condition That Most Commonly Narrows the Blood Vessel in the Legs (XATOC)

Coronary Artery Disease | Peripheral Artery Disease

Spain, Belgium, Italy, Korea, Republic of, Russian Federation, Taiwan, China, Colombia, Switzerland, Slovenia
Massachusetts General Hospital

Completed

Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation (NEW-AF)

Stroke | Atrial Fibrillation | Bleeding

United States
Bayer

Completed

A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With Warfarin (RENOVATOR)

Non-valvular Atrial Fibrillation (NVAF)

Korea, Republic of
Mazandaran University of Medical Sciences

Completed

Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS) (AREST-ESUS)

Stroke | Prevention

Iran, Islamic Republic of
Daiichi Sankyo, Inc.

Completed

Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study

Deep Vein Thrombosis | Venous Thromboembolism

Spain, United States, United Kingdom, India, France, Canada, Italy, Lebanon, Turkey
Kyushu University
Daiichi Sankyo Co., Ltd.

Completed

Clinical Trial to Investigate Safety and Efficacy of Edoxaban in Patients With CTEPH (KABUKI)

CTEPH

Japan
Takeshi Morimoto

Completed

Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study (ONCO DVT)

Neoplasms | Venous Thrombosis | Anticoagulant

Japan
Alliance Foundation Trials, LLC.
Patient-Centered Outcomes Research Institute

Completed

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer (CANVAS)

Cancer | Venous Thromboembolism | Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE) | Blood Clot

United States
Race Oncology Ltd
Astex Pharmaceuticals, Inc.

Withdrawn

A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS (BISECT)

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Higher Risk Myelodysplastic Syndrome

Australia
Intermountain Health Care, Inc.

Terminated

Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis (ARM-DVT)

Deep Vein Thrombosis | Venous Thromboembolism | Deep Venous Thrombosis | Thrombus | Upper Extremity Deep Venous Thrombosis

United States
Scott C. Woller, MD
Bristol-Myers Squibb; University of Utah

Completed

Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome (ASTRO-APS)

Thrombosis | Antiphospholipid Syndrome

United States
Maatschap Cardiologie Zwolle
Diagram B.V.

Completed

Rivaroxaban Plus Aspirin in Patients With Chronic Coronary Syndrome and High Ischemic Risk

Coronary Artery Disease (CAD) | Peripheral Arterial Disease (PAD)

Netherlands
University of North Carolina, Chapel Hill
American College of Clinical Pharmacy

Completed

A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic Syndrome

Nephrotic Syndrome | Membranous Nephropathy

United States
Population Health Research Institute

Completed

Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease

Ischemic Stroke | Intracranial Atherosclerotic Disease

Canada
Hospital Universitari de Bellvitge
Baxter Healthcare Corporation; Spanish Society of Nephrology

Completed

Study of Apixaban in Patients Receiving Hemodiafiltration (HEMOCIONA)

Atrial Fibrillation | Hemodialysis Complication

Spain
Daiichi Sankyo, Inc.
Daiichi Sankyo (China) Holdings Co., Ltd.

Active, not recruiting

Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China (ETNA-AF-CHINA)

Non-valvular Atrial Fibrillation

China
Assistance Publique - Hôpitaux de Paris
Bristol-Myers Squibb

Active, not recruiting

API-CAT STUDY for APIxaban Cancer Associated Thrombosis (API-CAT)

Cancer-associated Thrombosis

France, Spain, Netherlands, Belgium, Austria, Greece, Switzerland, Canada, Italy, Poland, United Kingdom
Bayer

Completed

Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)

Venous Thrombosis | Deep Vein Thrombosis

Belgium, Israel, Italy, Spain, Switzerland, Colombia, New Zealand, Hungary, Canada, Sweden, Austria, Czechia, Germany, Poland, Netherlands, Peru, South Africa, Australia, Brazil
Shiraz University of Medical Sciences

Completed

Rivaroxaban Post Coronary Bypass Surgery

Post Coronary Bypass Surgery Patients

Iran, Islamic Republic of
Portola Pharmaceuticals
Merck Sharp & Dohme LLC

Completed

A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment

Renal Impairment

Germany
TAHO Pharmaceuticals Ltd.

Completed

Comparative Bioavailability Study of TAH3311 5 mg Oral Dissolving Film vs ELIQUIS® 5 mg Tablet in Healthy Volunteers (TAH-12288201)

Healthy Volunteers | Fasting | Fed

United States
Portola Pharmaceuticals

Completed

A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa

Bleeding

United States
Portola Pharmaceuticals

Completed

A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations

Healthy
Portola Pharmaceuticals

Terminated

A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing

Bleeding

United States
Portola Pharmaceuticals

Completed

A Human Phase I Absolute Bioavailability Study of PRT054021 in Healthy Male Volunteers

Healthy Subjects
Portola Pharmaceuticals

Completed

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study) (APEX)

Venous Thromboembolism (VTE)

Belgium, Israel, Italy, United States, France, Bulgaria, Australia, Germany, Russian Federation, Hungary, Singapore, Austria, Chile, Canada, United Kingdom, Czechia, Poland, Spain, Romania, Latvia, South Africa, Croatia, Serbia, Peru, U... and more
Portola Pharmaceuticals

Completed

Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter

Atrial Fibrillation | Atrial Flutter
Portola Pharmaceuticals

Completed

Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin (EXPLORE-Xa)

Atrial Fibrillation

United States, Canada
Portola Pharmaceuticals

Completed

Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)

Thromboembolism

Canada
Portola Pharmaceuticals

Completed

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4)

Healthy Volunteers

United States
Portola Pharmaceuticals

Completed

An Open-Label, Single-Dose, Mass-Balance Study to Assess the Disposition of 14C-Labeled PRT054021 in Healthy Male Subjects

Health Volunteers
Pfizer

Completed

Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea

Venous Thromboembolism

Korea, Republic of
Daiichi Sankyo, Inc.
Daiichi Sankyo Deutschland GmbH

Completed

Edoxaban in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ENCOURAGE-AF)

Non-valvular Atrial Fibrillation

Germany
Assistance Publique - Hôpitaux de Paris

Active, not recruiting

Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF (APERITIF)

Myocardial Infarction, Acute | Left Ventricular Thrombus

France
Atrial Fibrillation Network
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company; Deutsches Zentrum für...

Terminated

Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes (NOAH)

Atrial High Rate Episodes

Austria, Belgium, Bulgaria, Czechia, France, Germany, Greece, Hungary, Italy, Netherlands, Poland, Portugal, Romania, Spain, Sweden, Ukraine, United Kingdom, Denmark
Brigham and Women's Hospital

Completed

Replication of the ROCKET-AF Anticoagulant Trial in Healthcare Claims Data

Atrial Fibrillation

United States
Brigham and Women's Hospital

Completed

Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data

Venous Thromboembolism

United States
Brigham and Women's Hospital

Completed

Replication of the EINSTEIN-PE Anticoagulant Trial in Healthcare Claims Data

Pulmonary Embolism

United States
Brigham and Women's Hospital

Completed

Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data

Venous Thromboembolism

United States
Brigham and Women's Hospital

Completed

Replication of the RECORD1 Anticoagulant Trial in Healthcare Claims Data

Deep Vein Thrombosis, Pulmonary Embolus

United States

Search clinical trials for: Factor Xa inhibitors

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations